Insight

Marco Donia: Circadian rhythm, tumor infiltration of CD8+ T cells, and cancer immunotherapy

Photo from Marco Donia/LinkedIn

May 12, 2024, 17:41

Marco Donia: Circadian rhythm, tumor infiltration of CD8+ T cells, and cancer immunotherapy

Marco Donia,

“Circadian rhythm, tumor infiltration of CD8+ T cells, and cancer immunotherapy.
(Free access, Cell Press, 8 May 2024)

Key Points:

Rhythmic Infiltration: CD8+ T cells follow a daily infiltration pattern in mice, dictated by the circadian clock in endothelial cells.
Timing of therapy: In mice, administering T-cell therapy or immune checkpoint blockade (particularly for the first cycle) at specific times influence their efficacy.
Human studies: Evidence shows that time-of-day oscillations in immune cell infiltration also exist in human tumors.

Take home:

Challenging the immune system at a specific time of day may influence the quality and the quantity of the response. Further studies in humans are warranted.

What is known from human studies?

Retrospective studies indicate that clinical outcomes of immunotherapy in humans can be influenced by the timing of the infusion (open access meta-analysis).

Time of the day for infusion is an ‘influencer’ of cancer Immunotherapy.

Authors: Chen Wang, Qun Zeng, Zeynep Melis Gül, and collaborators (PI Christoph Scheiermann at University of Geneva.”

Source: Marco Donia/LinkedIn

A. Karaboué Abhishek D. Garg B. Duchemann C. Chouaïd Camilla Jandus cancer CD8+ T cells Cell Press Charna Dibner Chen Wang Christoph Scheiermann Coline Barnoud D.C. Qian F. Lévi Federico Simonetta J.B. Assié Mara Cenerenti Marco Donia Mengzhu Sun Mikaël J. Pittet Olivier Michielin OncoDaily Oncology P.F. Innominato Pei-Chun Hsueh Phil Cheng Ping-Chih Ho Qun Zeng Robert Pick Ruben Bill Sisi Wang Sofie Hedlund Moller Stefan Naulaerts Stéphane Jemelin Stephanie Hugues T. Landré University of Copenhagen University of Geneva Volodymyr Petrenko Yan Wu Z.S. Buchwald Zeynep Melis Gül Zhongwu Li Ziyang Su

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage